Molecular characterization of acquired tolerance of tumor cells to picropodophyllin (PPP)

PLoS ONE

Volumn 6, Issue 3, 2011, Pages

  Hashemi, Jamileh ^a   Worrall, Claire ^a   Vasilcanu, Daiana ^a   Fryknäs, Mårten ^b   Sulaiman, Luqman ^a   Karimi, Mohsen ^a   Weng, Wen Hui ^a,c   Lui, Weng Onn ^a   Rudduck, Christina ^a,d   Axelson, Magnus ^a   Jernberg Wiklund, Helena ^b   Girnita, Leonard ^a   Larsson, Olle ^a   Larsson, Catharina ^a  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^b UPPSALA UNIVERSITY   (Sweden)

^c NATIONAL TAIPEI UNIVERSITY OF TECHNOLOGY   (Taiwan)

^d CHILDREN S HOSPITAL AT WESTMEAD   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; LIPOFECTAMINE; MESSENGER RNA; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PICROPODOPHYLLIN; PROTEIN BCL 2; SMALL INTERFERING RNA; UNCLASSIFIED DRUG; DRUG DERIVATIVE; MYC PROTEIN; PODOPHYLLOTOXIN;

ARTICLE; CANCER CELL; CELL DEATH; CELL LINE; CELL VIABILITY; CONTROLLED STUDY; DNA HYBRIDIZATION; DNA METHYLATION; DRUG DOSE INCREASE; DRUG TOLERANCE; FLUORESCENCE IN SITU HYBRIDIZATION; GENE AMPLIFICATION; GENE EXPRESSION PROFILING; GENETIC REGULATION; GENOTYPE; HOMOZYGOSITY; HUMAN; HUMAN CELL; IN VITRO STUDY; METAPHASE; MOLECULAR GENETICS; ONCOGENE; ONCOGENE ALDH1A3; ONCOGENE ANXA1; ONCOGENE COX6A1; ONCOGENE MAPK; ONCOGENE ME1; ONCOGENE NFIX; ONCOGENE RAB5A; ONCOGENE TAP2; ONCOGENE TLR4; REAL TIME POLYMERASE CHAIN REACTION; ALLELIC IMBALANCE; CHROMOSOME ABERRATION; CLUSTER ANALYSIS; COMPARATIVE GENOMIC HYBRIDIZATION; COPY NUMBER VARIATION; DRUG EFFECT; DRUG RESISTANCE; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; NEOPLASM; REPRODUCIBILITY; SPECTRAL KARYOTYPING; TUMOR CELL LINE;

ALLELIC IMBALANCE; CELL LINE, TUMOR; CHROMOSOME ABERRATIONS; CLUSTER ANALYSIS; COMPARATIVE GENOMIC HYBRIDIZATION; DNA COPY NUMBER VARIATIONS; DNA METHYLATION; DRUG RESISTANCE, NEOPLASM; GENE EXPRESSION REGULATION, NEOPLASTIC; GENOTYPE; HUMANS; IN SITU HYBRIDIZATION, FLUORESCENCE; METAPHASE; NEOPLASMS; PODOPHYLLOTOXIN; PROTO-ONCOGENE PROTEINS C-MYC; REPRODUCIBILITY OF RESULTS; RNA, SMALL INTERFERING; SPECTRAL KARYOTYPING;

EID: 79952685382     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0014757     Document Type: Article

References (41)

1. Longley DB, Johnston PG, (2005) Molecular mechanisms of drug resistance. J Pathol 205: 275-292.
2. Glasspool RM, Teodoridis JM, Brown R, (2006) Epigenetics as a mechanism driving polygenic clinical drug resistance. Br J Cancer 94: 1087-1092.
3. Roberti A, La Sala D, Cinti C, (2006) Multiple genetic and epigenetic interacting mechanisms contribute to clonally selection of drug-resistant tumors: current views and new therapeutic prospective. J Cell Physiol 207: 571-581.
4. Strathdee G, (2007) Epigenetic markers and response to chemotherapy in cancer. Dis Markers 23: 43-49.
5. Pang ST, Weng WH, Flores-Morales A, Johansson B, Pourian MR, et al. (2006) Cytogenetic and expression profiles associated with transformation to androgen-resistant prostate cancer. Prostate 66: 157-172.
6. Zheng T, Wang J, Chen X, Liu L, (2010) Role of microRNA in anticancer drug resistance. Int J Cancer 126: 2-10.
7. Vasilcanu D, Weng WH, Girnita A, Lui WO, Vasilcanu R, et al. (2006) The insulin-like growth factor-1 receptor inhibitor PPP produces only very limited resistance in tumor cells exposed to long-term selection. Oncogene 25: 3186-3195.
8. Girnita A, Girnita L, del Prete F, Bartolazzi A, Larsson O, et al. (2004) Cyclolignans as inhibitors of the insulin-like growth factor-1 receptor and malignant cell growth. Cancer Res 64: 236-242.
9. Menu E, Jernberg-Wiklund H, De Raeve H, De Leenheer E, Coulton L, et al. (2007) Targeting the IGF-1R using picropodophyllin in the therapeutical 5T2MM mouse model of multiple myeloma: beneficial effects on tumor growth, angiogenesis, bone disease and survival. Int J Cancer 121: 1857-1861.
10. Menu E, Jernberg-Wiklund H, Stromberg T, De Raeve H, Girnita L, et al. (2006) Inhibiting the IGF-1 receptor tyrosine kinase with the cyclolignan PPP: an in vitro and in vivo study in the 5T33MM mouse model. Blood 107: 655-660.
11. Nussbaum T, Samarin J, Ehemann V, Bissinger M, Ryschich E, et al. (2008) Autocrine insulin-like growth factor-II stimulation of tumor cell migration is a progression step in human hepatocarcinogenesis. Hepatology 48: 146-156.
12. Duan Z, Choy E, Harmon D, Yang C, Ryu K, et al. (2009) Insulin-like growth factor-I receptor tyrosine kinase inhibitor cyclolignan picropodophyllin inhibits proliferation and induces apoptosis in multidrug resistant osteosarcoma cell lines. Mol Cancer Ther 8: 2122-2130.
13. Klinakis A, Szabolcs M, Chen G, Xuan S, Hibshoosh H, et al. (2009) Igf1r as a therapeutic target in a mouse model of basal-like breast cancer. Proc Natl Acad Sci U S A 106: 2359-2364.
14. Yin S, Girnita A, Stromberg T, Khan Z, Andersson S, et al. (2010) Targeting the insulin-like growth factor-1 receptor by picropodophyllin as a treatment option for glioblastoma. Neuro Oncol 12: 19-27.
15. Economou MA, Wu J, Vasilcanu D, Rosengren L, All-Ericsson C, et al. (2008) Inhibition of VEGF secretion and experimental choroidal neovascularization by picropodophyllin (PPP), an inhibitor of the insulin-like growth factor-1 receptor. Invest Ophthalmol Vis Sci 49: 2620-2626.
16. Economou MA, Andersson S, Vasilcanu D, All-Ericsson C, Menu E, et al. (2008) Oral picropodophyllin (PPP) is well tolerated in vivo and inhibits IGF-1R expression and growth of uveal melanoma. Invest Ophthalmol Vis Sci 49: 2337-2342.
17. Vasilcanu R, Vasilcanu D, Sehat B, Yin S, Girnita A, et al. (2007) Insulin-like growth factor type-I receptor (IGF-1R) dependent phosphorylation of ERK1/2 but not Akt (PKB) can be induced by picropodophyllin. Mol Pharmacol.
18. Colon E, Zaman F, Axelson M, Larsson O, Carlsson-Skwirut C, et al. (2007) Insulin-like growth factor-I is an important antiapoptotic factor for rat leydig cells during postnatal development. Endocrinology 148: 128-139.
19. Conti L, Regis G, Longo A, Bernabei P, Chiarle R, et al. (2007) In the absence of IGF-1 signaling, IFN-gamma suppresses human malignant T-cell growth. Blood 109: 2496-2504.
20. Salazar-Onfray F, Nakazawa T, Chhajlani V, Petersson M, Karre K, et al. (1997) Synthetic peptides derived from the melanocyte-stimulating hormone receptor MC1R can stimulate HLA-A2-restricted cytotoxic T lymphocytes that recognize naturally processed peptides on human melanoma cells. Cancer Res 57: 4348-4355.
21. Hannelius U, Gherman L, Makela VV, Lindstedt A, Zucchelli M, et al. (2007) Large-scale zygosity testing using single nucleotide polymorphisms. Twin Res Hum Genet 10: 604-625.
22. Kytola S, Rummukainen J, Nordgren A, Karhu R, Farnebo F, et al. (2000) Chromosomal alterations in 15 breast cancer cell lines by comparative genomic hybridization and spectral karyotyping. Genes Chromosomes Cancer 28: 308-317.
23. SCN (1995) An International System for Human Cytogenetic Nomenclature, Mitelman F (ed) (S Karger, Basel 1995).
24. Weng WH, Lerner M, Grander D, Ahlen J, Villablanca A, et al. (2005) Loss of chromosome 13q is a frequently acquired event in genetic progression of soft tissue sarcomas in the abdominal cavity. Int J Oncol 26: 5-16.
25. Jonsson G, Staaf J, Olsson E, Heidenblad M, Vallon-Christersson J, et al. (2007) High-resolution genomic profiles of breast cancer cell lines assessed by tiling BAC array comparative genomic hybridization. Genes Chromosomes Cancer 46: 543-558.
26. Saal LH, Troein C, Vallon-Christersson J, Gruvberger S, Borg A, et al. (2002) BioArray Software Environment (BASE): a platform for comprehensive management and analysis of microarray data. Genome Biol 3: SOFTWARE0003.
27. Yang MC, Ruan QG, Yang JJ, Eckenrode S, Wu S, et al. (2001) A statistical method for flagging weak spots improves normalization and ratio estimates in microarrays. Physiol Genomics 7: 45-53.
28. Yang YH, Dudoit S, Luu P, Lin DM, Peng V, et al. (2002) Normalization for cDNA microarray data: a robust composite method addressing single and multiple slide systematic variation. Nucleic Acids Res 30: e15.
29. Autio R, Hautaniemi S, Kauraniemi P, Yli-Harja O, Astola J, et al. (2003) CGH-Plotter: MATLAB toolbox for CGH-data analysis. Bioinformatics 19: 1714-1715.
30. Huang da W, Sherman BT, Lempicki RA, (2009) Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources. Nat Protoc 4: 44-57.
31. Karimi M, Johansson S, Stach D, Corcoran M, Grander D, et al. (2006) LUMA (LUminometric Methylation Assay)--a high throughput method to the analysis of genomic DNA methylation. Exp Cell Res 312: 1989-1995.
32. Graham M, Adams JM, (1986) Chromosome 8 breakpoint far 3′ of the c-myc oncogene in a Burkitt's lymphoma 2;8 variant translocation is equivalent to the murine pvt-1 locus. EMBO J 5: 2845-2851.
33. Cadoret A, Desbois-Mouthon C, Wendum D, Leneuve P, Perret C, et al. (2005) c-myc-induced hepatocarcinogenesis in the absence of IGF-I receptor. Int J Cancer 114: 668-672.
34. Alevizopoulos K, Vlach J, Hennecke S, Amati B, (1997) Cyclin E and c-Myc promote cell proliferation in the presence of p16INK4a and of hypophosphorylated retinoblastoma family proteins. Embo J 16: 5322-5333.
35. Gil J, Kerai P, Lleonart M, Bernard D, Cigudosa JC, et al. (2005) Immortalization of primary human prostate epithelial cells by c-Myc. Cancer Res 65: 2179-2185.
36. Mullighan CG, Williams RT, Downing JR, Sherr CJ, (2008) Failure of CDKN2A/B (INK4A/B-ARF)-mediated tumor suppression and resistance to targeted therapy in acute lymphoblastic leukemia induced by BCR-ABL. Genes Dev 22: 1411-1415.
37. Gensler WJ, Gatsonis CD, (1966) The podophyllotoxin-picropodophyllin equilibrium. J Org Chem 31: 3224-3227.
38. Eun SY, Woo IS, Jang HS, Jin H, Kim MY, et al. (2008) Identification of cytochrome c oxidase subunit 6A1 as a suppressor of Bax-induced cell death by yeast-based functional screening. Biochem Biophys Res Commun 373: 58-63.
39. Yu H, Rohan T, (2000) Role of the insulin-like growth factor family in cancer development and progression. J Natl Cancer Inst 92: 1472-1489.
40. Parrizas M, Gazit A, Levitzki A, Wertheimer E, LeRoith D, (1997) Specific inhibition of insulin-like growth factor-1 and insulin receptor tyrosine kinase activity and biological function by tyrphostins. Endocrinology 138: 1427-1433.
41. Peruzzi F, Prisco M, Dews M, Salomoni P, Grassilli E, et al. (1999) Multiple signaling pathways of the insulin-like growth factor 1 receptor in protection from apoptosis. Mol Cell Biol 19: 7203-7215.